MORGAN STANLEY - PROQR THRAPEUTICS N V ownership

PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 63 filers reported holding PROQR THRAPEUTICS N V in Q1 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.0%.

Quarter-by-quarter ownership
MORGAN STANLEY ownership history of PROQR THRAPEUTICS N V
ValueSharesWeighting
Q3 2023$445,845
-44.5%
342,958
-30.8%
0.00%
Q2 2023$802,736
-41.9%
495,516
-23.6%
0.00%
Q1 2023$1,382,067
-1.4%
648,858
+71.4%
0.00%
Q4 2022$1,401,005
+294.6%
378,650
-20.7%
0.00%
Q3 2022$355,000
+14.1%
477,713
+19.8%
0.00%
Q2 2022$311,000
+69.9%
398,795
+97.5%
0.00%
Q1 2022$183,000
-37.5%
201,904
+451.3%
0.00%
Q4 2021$293,000
-68.5%
36,621
-67.0%
0.00%
Q3 2021$930,000
-64.1%
111,070
-71.1%
0.00%
Q2 2021$2,594,000
-18.3%
384,872
-19.9%
0.00%
Q1 2021$3,176,000
-25.4%
480,563
-52.6%
0.00%
-100.0%
Q4 2020$4,259,000
+313.1%
1,014,075
+371.4%
0.00%
Q3 2020$1,031,000
-56.5%
215,109
-44.8%
0.00%
-100.0%
Q2 2020$2,370,000
+112.2%
389,878
+91.6%
0.00%
Q1 2020$1,117,000
+6470.6%
203,482
+12113.8%
0.00%
Q4 2019$17,000
+21.4%
1,666
-29.7%
0.00%
Q3 2019$14,000
-22.2%
2,371
+18.3%
0.00%
Q2 2019$18,000
-98.3%
2,004
-97.4%
0.00%
Q1 2019$1,088,000
-78.0%
78,457
-75.0%
0.00%
-100.0%
Q4 2018$4,955,000
-37.0%
313,995
-22.7%
0.00%
-50.0%
Q3 2018$7,862,000
+270.7%
406,284
+39.8%
0.00%
+100.0%
Q2 2018$2,121,000
+200.0%
290,575
+26.3%
0.00%
Q1 2018$707,000
+23.4%
230,000
+29.5%
0.00%
Q4 2017$573,000
+16.7%
177,600
+75.3%
0.00%
Q3 2017$491,000
+52.5%
101,300
+63.7%
0.00%
Q2 2017$322,000
-33.7%
61,872
-36.3%
0.00%
Q1 2017$486,000
-4.7%
97,106
-6.6%
0.00%
Q4 2016$510,000
+125.7%
104,022
+207.8%
0.00%
Q3 2016$226,000
+53.7%
33,800
+11.6%
0.00%
Q2 2016$147,000
+2840.0%
30,300
+2930.0%
0.00%
Q1 2016$5,000
-99.0%
1,000
-97.0%
0.00%
Q3 2015$488,000
-21.9%
33,516
-10.6%
0.00%
Q2 2015$625,000
-38.4%
37,471
-19.2%
0.00%
Q1 2015$1,015,000
+12.7%
46,370
+11.5%
0.00%
Q4 2014$901,000
+231.2%
41,571
+162.4%
0.00%
Q3 2014$272,00015,8450.00%
Other shareholders
PROQR THRAPEUTICS N V shareholders Q1 2022
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,237,400$5,197,0001.55%
Prosight Management, LP 255,000$1,071,0000.50%
RTW INVESTMENTS, LP 5,009,768$21,041,0000.35%
Kerrisdale Advisers, LLC 453,182$1,903,0000.15%
Artal Group S.A. 1,196,218$5,024,0000.11%
COWEN AND COMPANY, LLC 285,696$1,200,0000.11%
Golden Green, Inc. 16,999$71,0000.07%
APOGEM CAPITAL LLC 15,855$67,0000.04%
ADAGE CAPITAL PARTNERS GP, L.L.C. 4,550,062$19,110,0000.04%
ALTRINSIC GLOBAL ADVISORS LLC 241,360$1,014,0000.03%
View complete list of PROQR THRAPEUTICS N V shareholders